Although profit (EBITDA) for this Q1 started off rather slowly, we understand that this is not a problem for the full year, g iven the business structure that is heavily weighted toward the second half of the year. In addition, each of the profits below operating profi t increased significantly due to a gain from the transfer of a subsidiary.
(Unit: Million JPY)
Revenue
Operating profit (Rate)
Profit before taxes (Rate)
Profit attributable to
owners of parent (Rate)
EBITDA (Margin)
FY2022 Q1
FY2023 Q1
Y-o-Y
5,776
6,698
+16%
1,081
2,546
+136%
(19%)
(38%)
1,120
2,552
+128%
(19%)
(38%)
765
2,040
+167%
(13%)
(31%)
1,521
1,679
+10%
(26%)
(25%)
3
Note: IFRS-based
EBITDA: Operating profit + Depreciation and amortization costs ± Other profits and/or losses, EBITDA margin: EBITDA/Revenue
FY2023 Q1: Quarterly Consolidated Revenue/EBITDA
Given the strong performance in Q1 of the previous fiscal year, we believe that this Q1 is off to a good start in terms of bo th revenue and profit.
Quarterly Trends of Consolidated Revenue
Quarterly Trends of Consolidated EBITDA/margin
(Unit: Million JPY)
(Unit: Million JPY and %)
EBITDA
margin
26
26
25
+ 16%
8,266
7,482
6,698
6,128
6,135
6,283
5,776
5,020
4,530
Q1
Q2
Q3
Q4
Q1
Q2
Q3
Q4
Q1
FY2021
FY2022
FY2023
+ 10%
2,376
2,384
EBITDA
2,107
1,831
1,521
1,679
1,308
1,434
1,164
Q1
Q2
Q3
Q4
Q1
Q2
Q3
Q4
Q1
FY2021
FY2022
FY2023
Full-year EBITDA margin
Full-year EBITDA margin
Full-year EBITDA margin
29%
28%
30%
4
Note: IFRS-based
EBITDA: Operating profit + Depreciation and amortization costs ± Other profits and/or losses, EBITDA margin: EBITDA/Revenue
FY2023 Q1: Performance by Segment
Revenue and profit grew in all segments.
(Unit: Million JPY)
FY2022 Q1
FY2023 Q1
Y-o-Y
Healthcare-Big Data
Tele-medicine
Dispensing Pharmacy
Support
Adjustment
Revenue
3,749
4,497
+20%
EBITDA
1,124
1,294
+15%
(Margin)
(30%)
(29%)
Revenue
1,175
1,307
+11%
EBITDA
439
448
+2%
(Margin)
(37%)
(34%)
Revenue
910
969
+7%
EBITDA
47
87
+84%
(Margin)
(5%)
(9%)
Revenue
-58
-76
-
EBITDA
-90
-151
-
5
Note: IFRS-based
EBITDA: Operating profit + Depreciation and amortization costs ± Other profits and/or losses, EBITDA margin: EBITDA/Revenue
Attachments
Original Link
Original Document
Permalink
Disclaimer
JMDC Inc. published this content on 09 August 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 09 August 2023 06:22:01 UTC.
JMDC Inc. is a Japan-based company mainly engaged in the health big data business, telemedicine business and dispensing pharmacy support business. The Company operates in three business segments. The Health Big Data segment is engaged in the provision of receipt data analysis and health promotion solutions, and personal health information platforms, the build, management and analysis of medical databases such as receipt data and medical examination data, the build and sale of drug databases, and the development and provision of systems using drug databases for medical institutions. The Telemedicine segment is engaged in the provision of remote image diagnosis matching services, and infrastructure systems for remote image diagnosis. The Dispensing Pharmacy Support segment is engaged in the development and provision of business systems and electronic medication record for dispensing pharmacies, as well as the operation of dispensing pharmacies.
JMDC INC. 
